3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
7
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
113
Myeloid
29
Lymphoid
16
Classical hematology
3
Sarcoma
2
Plasma cell
2
Head & Neck
2
Breast
2
Thoracic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Uveal Melanoma
1
Melanoma
1
Head and Neck Neoplasms
1
Interventions
pembrolizumab
65
Nivolumab
59
Ipilimumab
33
Cyclophosphamide
23
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
fludarabine
13
cemiplimab
13
Opdualag
12
Blood Specimen Collection
11
binimetinib
10
aldesleukin
9
Radiosurgery
9
Interleukin-2
9
encorafenib
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Aminolevulinic Acid
6
Radiotherapy
5
Disulfides
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Azacitidine
×
Dermatologic
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled